Compare STVN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | RARE |
|---|---|---|
| Founded | 1949 | 2010 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 1.6B |
| IPO Year | 2021 | 2013 |
| Metric | STVN | RARE |
|---|---|---|
| Price | $15.78 | $16.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $19.46 | ★ $25.35 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $6.90 | $12.70 |
| Revenue Next Year | $2.38 | $29.06 |
| P/E Ratio | $27.15 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $12.05 | $12.73 |
| 52 Week High | $24.01 | $39.89 |
| Indicator | STVN | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 49.08 |
| Support Level | $13.12 | $14.11 |
| Resistance Level | $17.19 | $17.67 |
| Average True Range (ATR) | 1.10 | 0.90 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 42.74 | 37.06 |
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.